The trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1 preferentially in normal gastric mucosal cells but the co-expression of these proteins is deregulated in gastric cancer  by May, Felicity E.B. et al.
T
p
o
F
a
b
c
a
A
R
R
A
A
K
T
T
G
G
M
1
t
t
ﬁ
i
i
s
e
2
2
(
(
c
N
1
dThe International Journal of Biochemistry & Cell Biology 41 (2009) 632–640
Contents lists available at ScienceDirect
The International Journal of Biochemistry
& Cell Biology
journa l homepage: www.e lsev ier .com/ locate /b ioce l
he trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1
referentially in normal gastric mucosal cells but the co-expression
f these proteins is deregulated in gastric cancer
elicity E.B. Maya,b,∗, S. Michael Grifﬁnc, Bruce R. Westleya,b
Department of Pathology, University of Newcastle upon Tyne, Royal Victoria Inﬁrmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK
Northern Institute for Cancer Research, School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
Northern Oesophago Gastric Cancer Unit, Royal Victoria Inﬁrmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK
r t i c l e i n f o
rticle history:
eceived 16 April 2008
eceived in revised form 17 July 2008
ccepted 18 July 2008
vailable online 3 August 2008
eywords:
FIZ1
refoil proteins
astric mucosa
a b s t r a c t
The gastric tumour suppressor trefoil protein TFF1 is present as a covalently bound heterodimer with a
previously uncharacterised protein, TFIZ1, in normal human gastric mucosa. The purpose of this research
was ﬁrstly to examine the molecular forms of TFIZ1 present, secondly to determine if TFIZ1 binds other
proteins apart form TFF1 in vivo, thirdly to investigate if TFIZ1 and TFF1 are co-regulated in normal gastric
mucosa and fourthly to determine if their co-regulation is maintained or disrupted in gastric cancer. We
demonstrate that almost all humanTFIZ1 is present as aheterodimerwith TFF1 and that TFIZ1 is not bound
to either of the other two trefoil proteins, TFF2 and TFF3. TFIZ1 and TFF1 are co-expressed by the surface
mucus secretory cells throughout the stomach and the molecular forms of each protein are affected by
the relative abundance of the other. TFIZ1 expression is lost consistently, early and permanently in gas-astric cancer
etastasis
tric tumour cells. In contrast, TFF1 is sometimes expressed in the absence of TFIZ1 in gastric cancer cells
and this expression is associated with metastasis (lymph node involvement: p=0.007). In conclusion,
formation of the heterodimer between TFIZ1 and TFF1 is a speciﬁc interaction that occurs uniquely in
the mucus secretory cells of the stomach, co-expression of the two proteins is disrupted in gastric cancer
and expression of TFF1 in the absence of TFIZ1 is associated with a more invasive and metastatic pheno-
type. This indicates that TFF1 expression in the absence of TFIZ1 expression has potentially deleterious
ncer.
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. Introduction
Our interest in the trefoil factor interactions(z) 1 (TFIZ1) pro-
ein stems from the ﬁnding that it forms a heterodimer with the
refoil protein TFF1 (Westley et al., 2005). The protein was identi-
ed independently using two other approaches. It was described
n the Chinese literature as a gene whose expression is decreased
n gastric cancer (Du et al., 2003) and as a gene whose expres-
ion is increased following Helicobacter pylori eradication (Resnick
t al., 2006). TFIZ1 is an 18.3 kDa secreted protein (Westley et al.,
005) encoded by one of two closely related genes on chromosome
(2p14), also known as GDDR (down-regulated in gastric cancer)
Du et al., 2003, 2005), blottin (Otto et al., 2006) and gastrokine 2
GKN2) (Baus-Loncar et al., 2007).
∗ Correspondingauthor at:Northern Institute forCancerResearch, School ofClini-
al and Laboratory Sciences, TheMedical School, University of Newcastle upon Tyne,
ewcastle upon Tyne NE2 4HH, UK. Tel.: +44 191 246 4417; fax: +44 191 246 4301.
E-mail address: F.E.B.May@ncl.ac.uk (F.E.B. May).
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TFIZ1 is related toGKN1which is alsoknownasCA11 (Yoshikawa
tal., 2000),AMP-18 (Martinet al., 2003), foveolin (Oienetal., 2004)
nd TFIZ2 (Westley et al., 2005). Similarly to TFIZ1, the expression
f one isoform of GKN1 is also decreased by H. pylori (Nardone et
l., 2007; Resnick et al., 2006). The functions of TFIZ1 and GKN1
re not known, but it has been suggested that they are involved
n the protection of the gastric mucosa and it has been reported
hat peptide fragments of GKN1 are bothmitogenic andmotogenic
Tobacket al., 2003). TFIZ1andGKN1both contain aBrichosdomain
Sanchez-Pulido et al., 2002). This domain is approximately 100
mino acids long and it is found in a variety of proteins implicated
n dementia, respiratory distress and cancer.
TFF1 is a small (6.67kDa) secreted protein identiﬁed orig-
nally as an oestrogen-regulated mRNA in breast cancer cells
Masiakowski et al., 1982; May and Westley, 1986; Ribieras et al.,
Open access under CC BY license. 998). It is one of three trefoil proteins all of which contain one or
wo copies of the 42–43 amino acid trefoil domain that has six con-
erved cysteine residues (Ribieras et al., 1998; May and Westley,
997). TFF1 and TFF3 contain one trefoil domain while TFF2 con-
ains two domains.
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Trefoil proteins are synthesized by mucus secreting epithelia
nd are important in mucosal protection. The main site of expres-
ionofTFF1 innormal tissues is the stomach (Rioet al., 1988;Piggott
t al., 1991; Madsen et al., 2007). TFF1 has been shown to interact
irectlywithmucinsboth in vitroand in vivo (Tomasettoet al., 2000;
uchaud-Sparagano et al., 2004). TFF1 protects from experimen-
ally induced gastrointestinal damage and is thought to promote
estitution (Playfordet al., 1996;Marchbanket al., 1998). Its interac-
ionwith humanMUC5AC (Ruchaud-Sparagano et al., 2004), which
s proposed to strengthen the adherent mucus gel barrier (Thim et
l., 2002), is exploited by the Class I carcinogen H. pylori (Clyne et
l., 2004).
In contrast to the deﬁned loop structure of the trefoil domain,
he carboxy-termini of both TFF1 (Polshakov et al., 1997) and TFF3
Lemercinier et al., 2001) monomers are unstructured. TFF1 and
FF3 have an extra cysteine residue near the carboxy-terminus
hat mediates intermolecular interactions (Fig. 1A). TFIZ1 has an
dd number of cysteine residues (Westley et al., 2005) and the
FIZ1:TFF1 heterodimer contains an intermolecular disulphide
ond formed most probably between Cys38 of TFIZ1 and Cys58 of
FF1 (Fig. 1).
The predominant molecular form of TFF1 identiﬁed in human
astric mucosa is the heterodimer of ∼25kDa with TFIZ1, but it is
lso present as a monomer and homodimer (Ruchaud-Sparagano
t al., 2004; Newton et al., 2000). In TFF1 homodimers, the two
onomer units are connected by a ﬂexible linker comprising the
wo carboxy-termini (Chadwick et al., 1997; Williams et al., 2001).
he TFF1homodimer has greater activity than themonomer in vitro
nd in animalmodels (Prest et al., 2002;Marchbank et al., 1998). Of
he three molecular forms of TFF1 identiﬁed, the TFF1 homodimer
s bound most strongly to gastric mucins and interacts preferen-
iallywithMUC5AC (Ruchaud-Sparagano et al., 2004;Newton et al.,
000). H. pylori have been shown to interact with the TFF1 homod-
mer but not the TFF1 monomer, and it has been proposed that H.
ylori colonize the adherent mucus layer as a consequence of the
peciﬁc interaction with the TFF1 homodimer (Clyne et al., 2004).
The identiﬁcation of TFIZ1 as the partner of TFF1 in the het-
rodimer raises several interesting biological questions about this
rotein. In this study, the spatial expression of TFIZ1 and themolec-
lar forms of TFIZ1 in the stomach are deﬁned, and the speciﬁcity of
he TFIZ1 TFF1 interaction is investigated. The patterns of expres-
ion of TFIZ1 and TFF1 in gastric cancer are also examined as this
ould shed light on the contribution of TFIZ1 to the tumour sup-
ressor activity of TFF1.
. Materials and methods
.1. Collection of gastric samples
Ethical permission for the studies was obtained from the Joint
ewcastle Health Hospitals/University of Newcastle upon Tyne
thical Committee. Informed consent for the use of normal gastric
ucosal samples was obtained from participants in this study.
.2. Preparation of cytosol from gastric mucosa
Normal gastric mucosa was taken from gastrectomy specimens
esected as primary therapy for gastric cancer. The mucosa was
aken from as far as was practicable from the tumour. Cytosol was
repared as described previously (Newton et al., 2000) except that
he tissue sample was pulverised after cooling in liquid nitrogen
sing a micro-dismembrator prior to homogenisation of the resul-
ant powder in inhibitor buffer using an ultra-turrax homogeniser.
ach 100mg of pulverised tissuewas suspended in 1ml of inhibitor
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uffer: 1mM iodoacetamide, 4mM PMSF, 5mM benzamidine
Cl, 10mM EDTA, 100mM -aminocaproic acid, 10mM N-ethyl
aleimide, 67mM sodium phosphate pH 6.5. After centrifuga-
ion for 1h at 100000× g, the cytosol was stored at −70 ◦C. The
rotein concentrations of the cytosols were measured using the
icinchoninic acid protein assay.
.3. Production of recombinant trefoil proteins
Recombinant human TFF1 and TFF3were produced by periplas-
ic expression from E. coli (May et al., 2003; Chadwick et al.,
997). The TFF1 and TFF3 monomers and dimers were puriﬁed by
combination of afﬁnity chromatography, anion exchange chro-
atography and gel ﬁltration (May et al., 2000). Recombinant
uman TFF2 was produced by secretion from P. pastoris. Non gly-
osylated and glycosylated TFF2 were puriﬁed by cation and anion
xchange and afﬁnity chromatography.
.4. Preparation of trefoil factor family protein and TFIZ1
ntibodies
Micewere immunizedwith correctly folded TFF1 or TFF3 dimer
r TFF1 or TFF2 peptides. Hybridoma cell lines were produced and
creened by ELISA (Westley et al., 2005; Pu et al., 2004). A TFIZ1
eptide of 15 amino acids that was predicted to be immunogenic
as synthesized, conjugated to KLH and used to immunize rabbits.
ntibody production and titre were monitored by ELISA.
.5. ELISA
Microtitre plate wells were coated with 50l of 200ng/ml
eptide or 400ng/ml trefoil protein and processed essentially as
escribedpreviously (Pu et al., 2004). Plateswerewashed and incu-
ated with TFF1 monoclonal antibody hybridoma supernatant or
FIZ1antisera followedby theappropriate secondaryantibodycon-
ugated to alkaline phosphatase. The reaction was visualized with
ara-nitro phenyl phosphate (Pu et al., 2004).
.6. Immunoprecipitation
TFF1 monoclonal antibodies were puriﬁed on protein A
epharose from protein-free hybridoma supernatant and conju-
ated to protein G Sepharose using disuccinimidyl suberate. TFIZ1
olyclonal antiserawere afﬁnity puriﬁedon thebasis of immunore-
ctivity with the immunizing peptides prior to conjugation to
rotein G Sepharose. Cytosols, prepared as described previously
Newton et al., 2000), were preabsorbed with protein G Sepharose
nd incubated with the conjugated antibodies in 300mM NaCl,
00mM Tris–HCl, pH 8.0, 0.2% Nonidet-P40 at 4 ◦C overnight.
he immunoprecipitatedproteinswere collected by centrifugation,
ashed 3 times in the above buffer and eluted in non-reducing
ample buffer (Pierce).
.7. Protein gel electrophoresis and Western transfer analysis
Proteins were electrophoresed on gradient polyacrylamide gels
nd transferred to PVDF membranes as described previously
Chadwick et al., 1997). Proteins were boiled for 5min in the
bsence or presence of-mercaptoethanol prior to electrophoresis.
ilterswere incubatedwith TFF1, TFF2or TFF3monoclonal antibod-
es (Westley et al., 2005;May et al., 2004) or TFIZ1 rabbit antiserum
iluted in 5% milk, followed by alkaline phosphatase-conjugated
econdary antibodies and the immunological reaction developed
ith nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phos-
hate (Chadwick et al., 1995).
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Fig. 1. Co-immunoprecipitation of TFF1 with TFIZ1 antiserum. The amino acid sequences of mature TFIZ1 and TFF1 are shown (A) with the cysteine residues involved in the
intermolecular disulphide bond indicated by downward pointing arrows. Cysteine residues are shown in bold and are boxed. Rabbits were immunized with a synthetic 15
residue TFIZ1 peptide predicted to be located in a solvent accessible region of the protein. TFIZ1 peptide, and recombinant TFF1, TFF2 and TFF3 were coated onto ELISA plates
in 50mM sodium bicarbonate pH 9.5. Wells were incubated with pre-immune rabbit serum (() B) or TFIZ1 antiserum (() B) or with mouse IgG (() C) or puriﬁed anti TFF1
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astric cytosol. Aliquots of gastric cytosol (Cyt.), immuno-depleted cytosol (Depl. Cy
els without (non-reducing) or after (reducing) prior incubation with -mercaptoe
ntibody. The positions of the molecular mass markers are shown on the left and th
.8. Immunohistochemistry
Sections of formalin-ﬁxed, parafﬁn-embedded gastric mucosa
ere processed as described previously except that heat retrieval
as for 1 or 3.5min in a pressure cooker in 10mM sodium cit-
ate, pH 6.0 (Crosier et al., 2001). Endogenous biotin was blocked
ith theDakoCytomationblocking system. The sectionswere incu-
ated with the primary antibodies for 1h, with the secondary
ntibody for 30min and with avidin–biotin immunoperoxidase
omplex (Vector laboratories) for 30min at room tempera-
3
F
mphosphatase-conjugated secondary antibody. TFIZ1was immunoprecipitated from
d TFIZ1 immunoprecipitate (TFIZ1 Ippte.) were electrophoresed on polyacrylamide
l (D). The proteins were transferred to PVDF membrane and incubated with TFF1
s of TFF1 on the right of the panels.
ure, developed with diaminobenzidine and counterstained with
aematoxylin.
. Results.1. Preparation and evaluation of TFIZ1 antibodies
The sequence of secreted 18.3 kDa TFIZ1 protein is shown in
ig. 1A. Speciﬁc TFIZ1 antiserawere raised to enable us to study the
olecular forms of TFIZ1 and their expression in normal andmalig-
f Biochemistry & Cell Biology 41 (2009) 632–640 635
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ant gastrointestinal mucosa. The effectiveness and speciﬁcity of
he TFIZ1 antisera and TFF1 monoclonal antibodies were tested by
LISA (Fig. 1B and C). There was a strong reaction against the TFIZ1
eptide and no reaction against TFF1, TFF2 or TFF3 recombinant
rotein. The TFF1 monoclonal antibody was speciﬁc for TFF1 and
id not react with TFIZ1 peptide, TFF2 or TFF3. The TFIZ1 antiserum
as tested for its ability to immunoprecipitate the TFF1:TFIZ1 het-
rodimer from protein extracts of normal human gastric mucosa.
liquots of human gastric cytosol, of the same cytosol after removal
f the proteins that were bound by the TFIZ1 antisera, and of
he proteins immunoprecipitated by the TFIZ1 antisera were elec-
rophoresed under non-reducing conditions, transferred to PVDF
embrane and incubated with TFF1 antibody (Fig. 1D). The TFF1
eterodimer is present in all three samples which indicates that
ome but not all of the TFF1:TFIZ1 heterodimer has been immuno-
recipitated by the TFIZ1 antisera. Analysis after electrophoresis
nder reducing conditionswith a TFF1 antibody conﬁrms that TFF1
as been co-immunoprecipitated by the TFIZ1 antiserum (Fig. 1D).
ontrol experiments in which protein extracts of normal gastric
ucosa were incubated with the pre-immune serum did not co-
mmunoprecipitate TFF1.
.2. Location of TFIZ1 in the gastric mucosa
Thepredominant formof TFF1extracted fromthenormal gastric
ucosa is a heterodimerwith TFIZ1. It is likely that the heterodimer
s formed intra-cellularly in single cells but it is possible, because
n extract would contain proteins secreted from cells at the base of
astric glands and from cells in the foveolae, that it is formed after
ecretion into the extra cellular environment following the synthe-
is of the two proteins in separate cell types. In addition, TFIZ1may
e expressed more widely than TFF1 and form heterodimers with
ther proteins in cells that do not express TFF1. To investigate this,
he localisation of TFIZ1 and that of three trefoil proteinswas deter-
ined by immunohistochemistry in mucosal sections from differ-
nt regions of the stomach. Typical results obtained with sections
f gastric body and antrum are shown in Fig. 2. TFF1 was localised
ith the monoclonal antibody used previously to purify the het-
rodimer, TFF2 and TFF3 using monoclonal antibodies, and TFIZ1
ith the polyclonal antibody described in Section 2 and above.
TFIZ1 was expressed by mucus secreting epithelial cells along
hemucosal surface and in the foveolae throughout the stomach in
ll cases examined (Fig. 2). It was not detected in the neck region or
asal portion of gastric glands or in the submucosa. The expression
roﬁle of TFF1 coincided with that of TFIZ1. TFF2 was expressed in
ucus neck cells and in cells in the basal portion of gastric glands.
FF3was not detected in normal gastric mucosal cells in this study.
FIZ1, like TFF1, was detected in the cytoplasm and in mucus glob-
les in the apical region of the secretory cells (Fig. 2). There was
diffuse immuno-reaction in the cytoplasm towards the basolat-
ral surface of the cells and a more intense immuno-reaction in
ucus globules towards the apical surface. These results, therefore,
emonstrate consistent co-localisation of TFIZ1 and TFF1 in speciﬁc
ucus secreting epithelial cells of the normal human stomach.
.3. Interaction of TFIZ1 with the trefoil proteins TFF2 and TFF3
The possibility that TFIZ1 forms heterodimers in vivo with the
ther two human trefoil proteins was pursued in further experi-
ents for two reasons. The ﬁrst was that the murine orthologue
f TFIZ1 was identiﬁed recently in an in vitro experiment, lig-
nd blot analysis, as the molecular partner of TFF2 even though
FF2 does not contain a free cysteine residue. The second was
hat TFF3, like TFF1, contains an unpaired cyteine residue close to
ts carboxy-terminus and can also form homodimers. TFIZ1 was Fi
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mig. 3. Investigationof interactionbetweenTFIZ1andTFF1, TFF2orTFF3 inhumanga
FF1, glycosylated TFF2 (gTFF2) or TFF3 and of gastric cytosol (Cyt.), immuno-deplet
n polyacrylamide gels after incubation with -mercaptoethanol. The proteins we
B) or TFF3 antibody (C). The positions of the molecular mass markers are shown on
mmunoprecipitated from gastric cytosol under non-denaturing
onditions, and analysed with TFF1, TFF2 and TFF3 antibodies after
lectrophoresis under reducing conditions and Western transfer
Fig. 3). TFF1 was co-immunoprecipitated by the TFIZ1 antibody
Fig. 3A). In contrast, TFF2 and TFF3 were not. TFF2 was detected
eadily in whole and immuno-depleted gastric cytosol but was not
etected in the TFIZ1 immunoprecipitate (Fig. 3B). In the reciprocal
xperiment in which TFF2 was immunoprecipitated from human
astric cytosol with a speciﬁc TFF2 monoclonal antibody, no TFIZ1
as detected in the immunoprecipitate (data not shown). TFF3was
ot detected in gastric cytosol or in the proteins immunoprecipi-
ated by TFIZ1 antiserum (Fig. 3)..4. Speciﬁcity of dimer formation between TFIZ1 and TFF1
Both TFF1 and TFIZ1 contain an odd number of cysteine residues
nd each, therefore, contains one free cysteine which is poten-
s
t
m
m
a
ig. 4. TFIZ1 is present as a monomer and a heterodimer in human gastric mucosa. TFF
mmuno-depleted cytosol (Depl. Cyt.) and TFF1 immunoprecipitate (TFF1 Ippte.) were elec
ith-mercaptoethanol. The proteinswere transferred to PVDFmembrane and incubated
ass markers are shown on the left and of the different forms of TFIZ1 on the right of theucosa. TFIZ1was immunoprecipitated fromgastric cytosol. Aliquots of recombinant
osol (Depl. Cyt.) and TFIZ1 immunoprecipitate (TFIZ1 Ippte.) were electrophoresed
sferred to PVDF membrane and incubated with TFF1 antibody (A), TFF2 antibody
eft and of the trefoil proteins on the right of the panels.
ially able to form homo- or heterodimers. Immunoprecipitation
xperiments were used to determine the major molecular forms
f each protein and to examine the promiscuity of TFIZ1 to form
eterodimers with non-trefoil proteins in gastric mucosa.
Aliquots of cytosol from normal human gastric mucosa, TFF1
mmuno-depleted cytosol and proteins immunoprecipitated by
FF1 antibody were analysed by Western transfer analysis under
on-reducing (Fig. 4A and B) and reducing (Fig. 4C) conditions.
hemajor TFF1 immuno-reactive protein bandunder non-reducing
onditions is the heterodimer with TFIZ1 and all was removed
y immunoprecipitation (Fig. 4A). TFIZ1 antisera detected two
rotein bands (Fig. 4B) in gastric cytosol. The antibody reacts
trongly with a protein band of ∼25kDa that co-migrates with
he TFF1:TFIZ1 heterodimer and more weakly with a more rapidly
igrating protein band. The TFIZ1 antibody reacts only with the
ore rapidlymigrating band in the TFF1 immuno-depleted cytosol
nd only with the ∼25kDa protein band in the TFF1 immunopre-
1 was immunoprecipitated from gastric cytosol. Aliquots of gastric cytosol (Cyt.),
trophoresed on polyacrylamide gels without (A and B) or after (C) prior incubation
with TFF1 antibody (A) or TFIZ1 antiserum (B and C). The positions of themolecular
panels.
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ipitate. These results are consistent with TFIZ1 being present in
t least two molecular forms in normal human mucosa: as a het-
rodimer with TFF1 that is immunoprecipitated by TFF1 speciﬁc
ntibodies and as a TFIZ1 monomer that is not immunoprecipi-
ated by TFF1 antibody. No other molecular forms were detected
uggesting that TFIZ1 does not readily form heterodimers with
ther proteins nor does it have a propensity to form homodimers.
estern transfer analysis of the same samples under reducing con-
itions with TFIZ1 antibody (Fig. 4C) revealed a single protein, that
igrates more slowly than would be predicted from its theoretical
olecular mass of 18.3 kDa as observed previously (Westley et al.,
005).
To examine the variability of TFIZ1 andTFF1expressionbetween
ndividuals, gastric mucosal extracts of nine individuals were anal-
sed by Western transfer analysis. TFIZ1 was detected in variable
mounts in all nine samples analysed (Fig. 5A). Highest levels of
FIZ1 were detected in cytosols 1, 2, 3, 5, 6 and 9 and lowest lev-
ls in 4 and 7. Analysis under non-reducing conditions indicated
rstly that the TFF1:TFIZ1 heterodimer was present in all samples
ut the amount differed and secondly that the ratio of TFIZ1 in the
onomeric formand theTFF1:TFIZ1heterodimeric formvaried. For
xample, the majority of TFIZ1 is in the monomeric form in cytosol
whereas the majority is in the heterodimeric form in cytosol 7
Fig. 5B). Analysis with the TFF1 antibody under non-reducing con-
itions conﬁrmed that the TFF1:TFIZ1 heterodimer is present in
ll samples (Fig. 5C). The heterodimer is the predominant form of
FF1, but in cytosol 8 which has relatively high concentrations of
FF1 compared to TFIZ1, the TFF1 homodimerwas readily detected.
his suggests that the relative amounts of the different molecu-
ar forms of TFF1 and TFIZ1 are determined in part by the relative
oncentrations of the two proteins so that if the concentration of
FIZ1 becomes limiting, TFF1 is more likely to form homodimers.
his experiment found no strong evidence for heterodimerisation
f TFF1 or TFIZ1 with other proteins.
.5. Expression of TFIZ1 and TFF1 in human gastric tumours
TFF1 is a gastric speciﬁc tumour suppressor. The protein to
hich it is bound in the normal stomach may impact on its
ehaviour in gastric cancer.We investigated co-expression of TFIZ1
nd TFF1 in a series of 15 primary gastric tumours and corre-
ponding metastatic tumour cells (Table 1). Both proteins were
o-expressed in non-neoplastic tissue adjacent to the primary
umours (Fig. 6). In seven of the cases examined, neither TFIZ1 nor
FF1were detected in the tumour cells. Expressionwas lost even in
ery early gastric cancers. For instance, in the case shown in Fig. 6A,
FIZ1 and TFF1 were detected readily in non-involved mucosa but
able 1
haracteristics of gastric tumours analysed by immunohistochemistry
umour Tumour size (cm) Differentiation Tumour stage Nodal status
1 6.0×5.0 Moderate T3 Positive
2 5.0×5.5 Poor T4 Positive
3 1.8×1.2 Well T1 Negative
4 2.5×1.5 Moderate–poor T3 Negative
5 5.5×3.5 Poor T3 Negative
6 1.8×1.8 Moderate–poor T2 Negative
7 3.5×5.0 Poor T3 Positive
8 4.5×4.5 Moderate T2 Positive
9 5.3×5.2 Poor T2 Negative
10 2.5×4.0 Well-moderate T2 Negative
11 <2×<1.0 Well T1 Negative
12 4.0×3.5 Poor T3 Positive
13 1.5×1.5 Moderate T2 Positive
14 3.0×5.0 Poor T3 Positive
15 4.2×3.0 Moderate–poor T3 Positive
Fig. 5. Expression of different molecular forms of TFIZ1 and TFF1 in normal
gastrointestinal mucosa. Aliquots of cytosol prepared from gastric mucosa were
electrophoresed on a polyacrylamide gel with (A) or without (B and C) prior incu-
b
m
p
f
w
s
f
i
i
c
tation with -mercaptoethanol. The separated proteins were transferred to PVDF
embrane and incubated with TFIZ1 antiserum (A and B) or TFF1 antibody (C). The
ositions of the molecular mass markers are shown on the left and of the different
orms of the proteins on the right of the panels.
ere not detected in carcinoma cells. In eight tumours, expres-
ion of TFF1 was detected in the absence of TFIZ1. For instance
or a small tumour (Fig. 6B), TFIZ1 expression was detected only
n the non-involved mucosa whereas TFF1 was detected in non-
nvolved mucosa and in both well and moderately differentiated
arcinoma cells. Similarly in a moderately to poorly differentiated
umour (Fig. 6C), TFIZ1 expression was detected only in adjacent
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Fig. 6. Loss of expression of TFIZ1 and TFF1 in human gastric adenocarcinoma. Sections of non-involved gastric mucosa, primary gastric tumour mass and of metastatic
carcinoma cells were processed for immunohistochemistry to locate TFIZ1 and TFF1. Sections are shown stained with haematoxylin and eosin (H&E) to allow visualization
of the cellular structures. Sections are from a small well differentiated tumour (A), a small well to moderately differentiated tumour (B), a 1.5 cm×2.5 cm moderately to
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coorly differentiated tumour (C), a 3.5 cm×5.0 cm poorly differentiated tumour wit
eposits (E). The photomicrograph of the 1.5 cm×1.5 cm well to moderately diffe
ifferentiated tumour cells to the left (B). The original magniﬁcations for the photo
ucosa, whereas TFF1 was detected in almost all carcinoma cells.
oss of or weak TFF1 expression in themain tumourmass was con-
rasted frequently with strong expression of TFF1 but not TFIZ1 by
arcinoma cells at the inﬁltrating edge or disseminated through the
ubmucosa. In an extreme example, TFF1 expression was absent in
he main tumour mass but was present in tumour cells that had
nﬁltrated the stroma (Fig. 6D). TFIZ1 expressionwas not detectable
ithin the inﬁltrating tumour cells that express TFF1 or in any
ther tumour cells. In a second example, TFIZ1 and TFF1 were
etected in adjacent normal mucosa, neither was detected in the
rimary tumour, but TFF1 was expressed by metastatic carcinoma
ells located within a lymph node from the greater curve and by
w
c
s
c
sl inﬁltration (D) and a 3.0 cm×5.0 cm poorly differentiated tumour withmetastatic
ted tumour shows well differentiated tumour cells on the right and moderately
raphs is ×200.
etastatic carcinoma cells that have invaded fat from the right
aracardial area (Fig. 6E).
The expression of TFF1 in the absence of TFIZ1 in inﬁltrating and
etastatic tumour cells suggested that this pattern of expression
ight be associated with lymph node involvement. Metastatic car-
inoma cells were not present in lymph nodes in ﬁve of the seven
ases in which neither protein was detected. In all eight cases, in
hich TFF1 was detected in the absence of TFIZ1, metastatic car-
inoma cells had disseminated to lymph nodes (Table 1). The data
howed that expression of TFF1 in the absence of TFIZ1 was asso-
iated with lymph node involvement (Fisher’s exact; p=0.007) and
uggested that it predisposes towards tumour spread.
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. Discussion
The TFF1:TFIZ1 heterodimer is themajor form of TFF1 in normal
uman gastric mucosa (Ruchaud-Sparagano et al., 2004; Newton
t al., 2000; Westley et al., 2005). In this study, we show that the
eterodimer is also the major form of TFIZ1 which suggests that
his covalent protein–protein interaction is speciﬁc for these two
roteins and that neither protein is signiﬁcantly promiscuous in
ts ability to form heterodimers with other proteins and that the
ormation of the TFF1:TFIZ1 heterodimer is critical for the nor-
al biological function of both proteins. The relative proportions of
oth TFIZ1 and TFF1 monomer and heterodimer varied somewhat
etween individuals. Interestingly, theproportionsof themolecular
orms of TFF1 and TFIZ1 can be affected by the relative abundance
f the other protein. For instance, if less TFIZ1 is expressed, more of
he TFF1 dimer is formed. This may have biological implications as
t is known that the TFF1 dimer stimulates themigration of tumour
ells (Prest et al., 2002).
The demonstration that TFF1, but not the other structurally
elated trefoil proteins, TFF2 or TFF3, is co-immunoprecipitated by
FIZ1 antiserumcombinedwith the co-immunoprecipitationof the
ajority of TFIZ1 from gastric cytosol by a TFF1 monoclonal anti-
ody and the inability of a TFF2 antibody to co-immunoprecipitate
FIZ1 with TFF2 suggest that in normal human gastric cells TFIZ1
eacts speciﬁcally with TFF1 and not with TFF2 or TFF3. In the case
f TFF2, TFIZ1 and TFF2 are synthesized in different cell types and
heterodimer, if formed, would probably not be stabilised by a
isulphide bond because TFF2 has no unpaired cysteine residue.
he murine orthologue of TFIZ1 was identiﬁed recently by lig-
nd blot analysis with a fusion protein of murine TFF2 which
uggested that TFIZ1 interacts with TFF2 (Otto et al., 2006). Our
esults are not consistent with this as TFF2 and TFIZ1 are not co-
ocalised in the gastric mucosa and there was no evidence for
TFF2:TFIZ1 heterodimer from co-immunoprecipitation experi-
ents. In the case of TFF3, which does contain a free cysteine
esidue in a similar position to TFF1, a TFF3:TFIZ1 heterodimer is
nlikely to be formed because TFF3 is absent from or expressed
t low levels in the normal stomach. There are also signiﬁcant
tructural differences between TFF1 and TFF3 which may pre-
lude the formation of a TFF3:TFIZ1 heterodimer (May et al.,
003).
TFIZ1 protein expression in the gastric mucosa is restricted to
ells that express TFF1. TFIZ1 is co-localised with TFF1 in mucus
ecretory cells on the surface and in the foveolae throughout the
ormal human stomach. The strongest immuno-reaction for both
FIZ1 andTFF1 iswithin themucus secretory vesicleswhich is com-
atible with our demonstration that the TFF1:TFIZ1 heterodimer is
resent in adherent gastric mucus (Newton et al., 2000).
This is the ﬁrst study of TFIZ1 protein expression in gastric can-
er and demonstrates that TFIZ1 expression is lost in gastric cancer
ven in very early tumours. This is consistent with an early report
n the Chinese literature that the expression of the mRNA that
ncodes the TFIZ1 protein is reduced in gastric cancer (Du et al.,
003). TFF1 protein expression is also lost in gastric tumours, but
n about half the cases in which TFIZ1 protein was not expressed,
FF1expressionwasdetected. In somecases, inwhichexpressionof
oth proteinswas absent in the primary tumour, TFF1 but not TFIZ1
as expressed in inﬁltrating andmetastatic tumour cells. The ﬁnd-
ng that TFF1 is expressed in the absence of TFIZ1 in some gastric
umours and further that an ability to express TFF1 but not TFIZ1 is
cquired by invasive cancer cells suggest that this phenotypemight
e associatedwith lymph nodemetastasis and poor prognosis. Our
emonstration of an association between TFF1 expression in the
bsence of TFIZ1 expression and lymphnode involvement supports
his contention.
A
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Work with TFF1-null mice showed that TFF1 is a gastric tumour
uppressor (Lefebvre et al., 1996). The gastric mucosa of TFF1-null
ice becomes thickened by three weeks of age and by ﬁve months
xhibits severe hyperplasia, dysplasia and absence of mucin. All
ice develop antropyloric adenomas and 30% develop adenocarci-
omas. Loss of TFF1 expression occurs frequently in human gastric
ancer (Henry et al., 1991; Muller and Borchard, 1993). TFF1 gene
nactivation occurs by loss of heterozygosity and hypermethyla-
ion of the TFF1 promoter (Park et al., 2000b; Fujimoto et al., 2000;
arvalho et al., 2002). Missensemutations in TFF1 have been found
n gastric cancers however their importance is uncertain (Carvalho
t al., 2002; Park et al., 2000a; Beckler et al., 2003).
In seeming contradiction to its proposed role as a tumour sup-
ressor, TFF1 is frequently over-expressed or expressed ectopically
y tumour cells (May and Westley, 1997). It has been suggested
hat TFF1 may be involved in tumour dissemination because it
timulates migration and invasion of tumour cells (Prest et al.,
002; Emami et al., 2001). Inappropriate TFF1 expression may also
romote tumourigenesis due to its anti-apoptotic and angiogenic
ctivities (Bossenmeyer-Pourie et al., 2002; Rodrigues et al., 2003).
FF1 expression is associated with increased incidence of breast
ancer metastasis to bone (Smid et al., 2006), high levels of TFF1
xpression in metastatic tumour cells renders it a reliable marker
f micrometastases (Mikhitarian et al., 2005) and expression is
ncreased in tumours that arise during the interval between routine
reast cancer screening (Crosier et al., 2001).
The dissociation of TFF1 and TFIZ1 protein expression in gastric
arcinoma cells could provide an explanation for the apparent con-
radiction that TFF1 expression is beneﬁcial in normal tissue but
etrimental in cancerous tissue (May and Westley, 1997). It may
lso reconcile the observation that a gastric tumour suppressor is
xpressed ectopically by other tumours and at high levels by a large
roportion of breast tumours including interval cancers (Henry et
l., 1991; Crosier et al., 2001; Rio et al., 1987; Foekens et al., 1994).
ur results suggest that expression of TFF1 in the absence of the
nteracting protein TFIZ1 confers an invasive phenotype on tumour
ells and that TFIZ1 may itself be a tumour suppressor or that it is
he formation of the heterodimer that is important for the tumour
uppressor activity of TFF1. The consistent, early and permanent
oss of TFIZ1 expression in human gastric tumours is supportive of
hese possibilities. Clearly, absence of TFIZ1 will affect the molecu-
ar forms of TFF1 produced and may favour production of the TFF1
imer which stimulates cancer cell motility and invasion. Our data
uggest that expression of TFIZ1 might ensure normal, beneﬁcial
unction of TFF1 whereas in the absence of TFIZ1, TFF1 promotes
nvasion.
In a recent expression microarray analysis of the effects of H.
ylori eradication on gene expression in gastric mucosal surface
pithelial cells, TFIZ1 mRNA was the most induced mRNA which
ndicates that TFIZ1 expression is reduced followingH. pylori infec-
ion (Resnick et al., 2006). If TFIZ1 has tumour suppressor activity,
eduction of TFIZ1 expression after H. pylori infection may explain
n part the carcinogenic role ofH. pylori in the progression to gastric
ancer. In addition, continued expression of TFF1 in the context of
oss of TFIZ1 expression induced by H. pylori infection could facil-
tate prolonged colonization of the mucus gel layer by H. pylori
Clyne et al., 2004). In the longer term, persistence of the imbalance
n TFIZ1 and TFF1 expression could increase the invasive behaviour
f any tumour induced.cknowledgements
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